Expression of bcl-2 and p53 in oncocytic (Hurthle cell) tumors of the thyroid: An immunohistochemical study

Endocrine Pathology

Volumn 9, Issue 2, 1998, Pages 117-123

  Kohli, Anupama ^a   Baker, Stephen P ^a,b   Patwardhan, Nilima A ^a   Khan, Ashraf ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Division of Medical Assistance   (United States)

Author keywords

Bc1 2; Hurthle cell tumors; Immunohistochemistry; P53

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; ENDOCRINE TUMOR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THYROID ADENOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROID TUMOR; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE;

EID: 0031818696     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02782604     Document Type: Article

References (22)

1. Rosen IB, Luk S, Katz I. Hürthle cell tumor behavior: Dilemma and resolution. Surgery 98:777-783, 1985.
2. Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH. Hürthle cell lesions of thyroid gland. Surg Gynecol Obstet 139:555-560, 1974.
3. Van Heerden J. Hürthle cell neoplasms [discussion]. Arch Surg 119:518-519, 1984.
4. Gossain K, Clark OH. Hürthle cell neoplasms. Arch Surg 119:515-518, 1984.
5. Bondeson L, Azavedo E, Bondeson AG, Caspersson T, Ljungberg O. Nuclear DNA content and behavior of oxyphil thyroid tumor. Cancer 58:672-675, 1986.
6. Flint A, Davenport RD, Lloyd RV, Beckwith AL, Thompson NW. Cytophotometric measurements of Hürthle cell tumors of the thyroid gland. Cancer 61:110-113, 1988.
7. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinomas. Am J Surg Pathol 17:375-381, 1993.
8. Soares P, Cameselle-Teijeiro J, Sobrinho-Simoes M. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology 24:205-210, 1994.
9. Czyz W, Joensuu H, Pylkkanen L, Klemi PJ. p53 protein, PCNA staining and DNA content in follicular neoplasms of the thyroid gland. J Pathol 174:267-274, 1994.
10. Donghi R, Longoni A, Pilotti S, Michieli P, Delia Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760, 1993.
11. Hosal SA, Apel RL, Freeman JL, Rosen IB, LiVolsi VA, Asa SL. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr Pathol 8:21-28, 1997.
12. Reed JC. Bc1-2 and regulation of programmed cell death. J Cell Biol 124:1-6, 1994.
13. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. BCL-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 172:337-342, 1994.
14. Pilotti S, Collini P, Del Bo R, Cattoretti G, Pierotti MA, Rilke F. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 18:1054-1064, 1994.
15. LiVolsi VA. Hürthle cell lesions. In: Surgical pathology of the thyroid. Philadelphia, PA: WB Saunders, 1990; 275-288.
16. Gundry SR, Bumey RE, Thompson NW, Llyod R. Total thyroidectomy for Hürthle cell neoplasm of the thyroid. Arch Surg 118:529-532, 1983.
17. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 47:337-339, 1994.
18. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, et al. Alteration of p53 and expression of WAF 1/p21 in human thyroid tumors. Thyroid 6:1-9, 1996.
19. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutation of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184, 1993.
20. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors: an immunohistochemical study using methacarn-fixed, paraffin-embedded tissue. Am J Pathol 140:145-153, 1992.
21. Jenkins JR, Rudge K, Chumakov P, Currie GA. The cellular oncogene p53 can be activated by mutagenesis. Nature 317:816-818, 1985.
22. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry. J Pathol 166:329,330, 1992.